Brazil’s health regulator grants Fiocruz approval to produce cannabidiol

The authorization is just a first step in Fiocruz's plans for research with cannabis, as it is interested in becoming a supplier of cannabidiol for the SUS.

RIO DE JANEIRO, BRAZIL - On Thursday, May 13, Fiocruz's Institute of Technology in Pharmaceuticals was granted final approval by the Brazilian Health Regulatory Agency (ANVISA) to produce cannabidiol - a medicinal derivative of marijuana.

The institution is the third to be granted this permission in the country. Currently, in Brazil, only the pharmaceutical company Prati-Donaduzzi and the newcomer to the market Nunature were authorized to produce or commercialize products derived from marijuana.

Prati has cannabidiol in three versions in its pharmacies, and Nunature is expected to hit the shelves only in July.

Cannabidiol is only one of the components . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?